Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML1854

Sigma-Aldrich

Banoxantrone dihydrochloride

≥98% (HPLC)

Sinonimo/i:

1,4-Bis[[2-(dimethyloxidoamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenedione, AQ4N dihydrochloride

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C22H28N4O6 · 2HCl
Numero CAS:
252979-56-9
Peso molecolare:
517.40
Numero MDL:
MFCD19690955
Codice UNSPSC:
12352200
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Condizioni di stoccaggio

desiccated

Colore

blue

Solubilità

H2O: 3 mg/mL, clear (warmed)

Temperatura di conservazione

2-8°C

Stringa SMILE

O=C1C2=C(C(NCC[N+](C)([O-])C)=CC=C2NCC[N+]([O-])(C)C)C(C3=C(O)C=CC(O)=C31)=O.[H]Cl.[H]Cl

InChI

1S/C22H28N4O6.2ClH/c1-25(2,31)11-9-23-13-5-6-14(24-10-12-26(3,4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30;;/h5-8,23-24,27-28H,9-12H2,1-4H3;2*1H
SBWCPHUXRZRTDP-UHFFFAOYSA-N

Applicazioni

Banoxantrone dihydrochloride has been used as an organic ligand during a self-assembled metal-organic coordinated nanoparticle (Cu–OCNP/Lap) synthesis. It has also been used for the preparation of supramolecularly functionalized graphene oxide for hypoxia-activated chemotherapy of cancer.

Azioni biochim/fisiol

Banoxantrone (AQ4N) is a hypoxia-activated prodrug of topoisomerase II inhibitor AQ4 (Bioreductive AQ4 precursor).
Banoxantrone dihydrochloride enhances the anti-tumor effect caused by radiation.
Hypoxia-activated prodrug of topoisomerase II inhibitor AQ4

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
017M4737V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Olivier Trédan et al.
Cancer research, 69(3), 940-947 (2009-01-30)
Hypoxic tumor cells are likely to be resistant to conventional chemotherapy, in large part because many anticancer drugs are unable to penetrate into poorly oxygenated tumor tissue. Here, we used quantitative immunofluorescence to study the distribution of mitoxantrone and AQ4N
Alshad S Lalani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(7), 2216-2225 (2007-04-04)
The antitumor activities and pharmacokinetics of the hypoxia-activated cytotoxin AQ4N and its metabolites were assessed in several preclinical models of pancreatic cancers. The cytotoxic effects of AQ4N prodrug and its bioreduced form, AQ4, were tested against multiple human tumor cell
Heather Nesbitt et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(7), 1797-1808 (2016-10-05)
Purpose: To understand the role of hypoxia in prostate tumor progression and to evaluate the ability of the novel unidirectional hypoxia-activated prodrug OCT1002 to enhance the antitumor effect of bicalutamide.Experimental Design: The effect of OCT1002 on prostate cancer cells (LNCaP
O P Friery et al.
British journal of cancer, 82(8), 1469-1473 (2000-04-26)
The ability of the bioreductive drugs AQ4N and tirapazamine to enhance the anti-tumour effect of cyclophosphamide was assessed in three murine tumour models. In male BDF mice implanted with the T50/80 mammary carcinoma, AQ4N (50-150 mg kg(-1)) in combination with

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.